We sought to identify early uses of blinding in therapeutic clinical trials of neurological disorders by multiple search methods. A 1784 report by Benjamin Franklin and others described the evaluation of the use of Mesmerism to treat neurological and other syndromes including headache and epilepsy, using blindfolds and screens. This report demonstrated the usefulness of blinding to reduce bias in clinical research, yet despite this early discovery, blinding was not widely accepted or routinely used until the 20 th century. Blinded clinical trials began to be used for various neurological syndromes in the 1950s, sporadically at first and then increasing in frequency in subsequent years. The reason for this delay is unclear, but we propose several hypotheses.
Introduction:
Blinding/masking the allocation of subjects to treatment groups in therapeutic clinical research is now a well-established method to reduce the chance of bias and erroneous conclusions about safety or efficacy. 1 
Methods
Books and articles covering the history of neurology and the history of clinical research were reviewed for the likely timeframe of introduction of blinding. [1] [2] [3] [4] [5] We searched PubMed, Google Scholar, and Project MUSE in early 2011 with combinations of the terms "neurology," "treatment," "blind," and "placebo."
During initial searches we identified 10 neurological disorders that appeared to be the most likely candidates for the earliest use of blinded trials, and repeated the searches substituting the name of each of these disorders for the term "neurology." We then reviewed articles from these searches from the 1950s and 1960s to find the earliest examples of blinding for each disorder, and reviewed the references of the included articles. For an estimated timeline, PubMed was then searched using the limit of "clinical trial" with the terms of each of the 10 neurological disorders, "treatment," and "blind" to determine the number of publications matching these search criteria for each decade after the 1950s; all the matching studies reported in the 1950s are discussed below. After the 1950s, only the initial reports for the 10 neurological disorders that had not already been reported are discussed below.
Results
We found one report from 1784, then a handful of reports from the 1950s, with a subsequent accelerating pace of reports as discussed below and estimated in Table 1 .
The first example that we could find of the use of blinding in a therapeutic clinical research study of Based on their initial findings, the commissioners asked, "Why did this agent produce no effect upon Genevieve Leroux, who was in a perpetual state of convulsions?" will have a natural explanation for these effects; at the least, we will have legitimate reasons to doubt that the real cause of these effects is magnetism."
They then discussed the role of skepticism on the placebo effect.
"These facts permitted the Commissioners to observe that magnetism has seemed to be worthless for those patients who submitted to it with a measure of incredulity; that the Commissioners, even when those with jittery nerves deliberately focused their attention elsewhere, having been armed with philosophical doubt that ought to accompany every examination, did in no way feel the impressions felt by the three lower-class patient, & they must have suspected that these impressions, even supposing them all to be real, They now sought to demonstrate a lack of effect with the opposite approach, "as facts are more conclusive than reasoning & provide more striking evidence." The Commissioners wanted to test how magnetism would work when the imagination was not at work. They set up an apartment with rooms adjoined by a door. The door itself was removed and covered with paper. They then invited a seamstress "whose sensitivity to magnetism was known" to come over but did not tell her that they had another test for her. The woman was A third single-blind study was the 1954 report of a four-way crossover study of artane, panparnit, hyoscine, and placebo for Parkinsonism. 10 In this study, "All medicaments, including placebo, were prepared in identical capsules which were not distinguishable in appearance... by the use of the placebo any tendency to respond because of the psychologic factors involved in treatment rather than the specific pharmacologic properties of the drug could also be evaluated."
Blinding in an epilepsy trial made its appearance in the 1955 report of a single-blind study of five drugs for "petit mal epilepsy," where each group was crossedover with placebo. 11 That same year a report appeared of the first double-blind neurology trial we could find of a new compound for Parkinsonism. 12 In an effort to reduce the placebo effect, all subjects were given "inert tablets resembling" the study drug, and "Patients who had responded to previous therapy but were no worse on the inert tablets could not be regarded as having In 1956, a double-blind study was reported of cortisone therapy for headache after pneumoencephalography. 13 In this study, the investigators performed In 1957, a study was reported of the use of digestive enzymes for multiple sclerosis that was, for the most part, double-blind. 14 It is probable, although rarely stated, that patients in these early studies were not informed that placebos were used. A 1958 report of a crossover study of benactyzine in patients with "violent tempers" and Parkinsonism stated that "No patients ever discovered that some of the tablets they were receiving were blanks." 15 It was not stated, however, how the authors knew this to be true. Knowledge of the placebo effect on both safety and efficacy outcomes was clearly expressed: "Once again this minor investigation shows that inert substances produce the same effects as drugs with pharmacological properties; they are useful to patients who believe they will get benefit from them, and they cause undesired side-effects; and the side effects may be present only with the inert tablets and not with the actual drug."
In the same issue of the British Medical Journal, another report appeared of a new compound tested with a placebo-controlled crossover design in patients with post-encephalitic Parkinsonism. 16 This report was notable for being the first we found that described the effectiveness of the blinding procedure for both subjects and investigators, while also hinting of early struggles and ethical issues encountered during blinded trials:
"It was decided to stop all current therapy for a day before the trial began. When this decision was taken it was not expected that withdrawal symptoms would be so troublesome. Actually they were severe in three cases... One of the three patients threatened suicide unless he was put back on his previous treatment. In other cases these symptoms may have prejudiced the patients against the new tablets... There was a slight difference in appearance between the two tablets, so that some of the doctors knew which was genuine and which dummy on the first day.
It is doubtful if any of the patients recognized the difference in appearance between the two tablets... In two cases withdrawal symptoms were severe, and the dummy tablet had to be discontinued and previous treatment In 1963, carisoprodol was studied in a doubleblind, placebo-controlled trial of multiple types of musculoskeletal disorders, including patients with sciatica, which appeared to also use randomization:
"Patients were admitted to the trial sequentially and were allocated to treatment with the drug or placebo by a system of randomized selection, adhered to throughout." 18 A double-blind stroke trial was also reported in 1963 of intravenous plasmin for thrombolysis of presumed ischemic stroke, a decade prior to computed tomography. 19 To avoid enrolling patients with hemorrhagic stroke, the subjects were "treated within isoniazid for pulmonary tuberculosis. 20 A 1964 report described a double-blind trial of Duchenne muscular dystrophy patients given a mixture of nucleotides and nucleosides intravenously and intramuscularly. 21 The authors noted the difficulties of assessing a therapy for this condition, due to the "enthusiastic response of a parent, distressed by the progressive disability seen in his child." In this study, the placebo group was given oral calcium lactate pills, but they were "not given inert intravenous infusions and intramuscular injections as it was felt that this was hardly justifiable; a similar plan was adopted by the blinding, which now dominate therapeutic research. 1, 22 In 1971, a double-blind study was reported of isoprinosine for amyotrophic lateral sclerosis. 23 The authors stated a common ethical concern with the use of placebo control groups, "Since the disease is progressive and the pathology presumably irreversible, moral issues were involved in a double-blind study. If some participants did not receive the medication, they would not derive benefit from the study." To address this, the investigators enacted a compromise solution: "The study was, therefore, set up that any patient who felt that the medicine he was taking was ineffective would be placed on the other one after a minimum of ninety days. This guaranteed that each participant would receive the true These 'improvements' are easy to understand in terms of the great psychological stress the patients were under and the hope that a potentially new medicine offered."
There appeared to be an accelerating rate of publication of therapeutic clinical trials using blinding for the 10 neurological conditions included in our search after the 1950s (Table 1) .
Discussion
In 1940, Israel Wechsler, one of the most respected neurologists of his time, reported the results of an unblinded and uncontrolled trial of vitamin E for patients with amyotrophic lateral sclerosis. 24, 25 He reported that "11 out of the 20 cases showed varying degrees of improvement. Two patients seem to have recovered, 4
showed marked degrees of improvement and 5 moderate degrees." One subject stands out: It is now known that Case 4 was Lou Gehrig, by whose name the disease is commonly known in the United States. Despite the reported results, other sources confirmed that his disease was progressive until it eventually killed him in 1941. 24 It seems that the temptation to believe and the desire to see positive States, mainstream doctors put forth streams of studies and arguments disproving these systems. 27 Oliver Wendell Holmes, for instance, called homeopathy a "kindred delusion" and set about systematically taking down each of its beliefs and tenets. 28 We believe that the studies we found are among the earliest therapeutic studies using blinding for neurological conditions. Headache, in particular, was likely to have been one of the earliest uses of blinding for any medical condition, as it is almost entirely a subjective disorder with strong psychological interplay.
However, our research has several limitations. We relied on databases rather than hand searching of all clinical trial reports of the several centuries in question, and because the indexing on these databases is inconsistent and incomplete, we could have missed even earlier blinded studies. Our understanding of the reason for the timing of the development of blinding is limited, primarily by the brief mentions of its justifications in the reports we found. Our quantification of the time course of blinded therapeutic clinical trials for the 10 neurological conditions we explored is likely representative, though not a complete picture, of the accelerating pace of publications of interest.
Conclusions
We found evidence that blinding in therapeutic clinical research for neurological disorders was discovered and well-reported in the 18 th century, but did not appear to enter modern trials until the 1950s, with increasing use in each subsequent decade. The cause for this delay is unclear. Perhaps, among so many other things, the neurologist Hughlings Jackson was correct when he said: "It takes 50 years to get a wrong idea out of medicine, and 100 years to get a right one into medicine." 29 
